현재 위치
Home
[원보]
복막투석 환자의 빈혈 관리에 있어 에리스로포이에틴 자극제의 사용현황 및 비교평가
A Comparative Study on Trends and Efficacy of Erythropoietin Stimulating Agents in Patient Receiving Peritoneal Dialysis
-
- 발행기관
- 한국임상약학회 바로가기
-
- 간행물
- 한국임상약학회지 KCI 등재 바로가기
-
- 통권
- 제24권 제3호 (2014.09)바로가기
-
- 페이지
- pp.206-212
-
- 저자
-
- 언어
- 영어(ENG)
-
- URL
- https://www.earticle.net/Article/A232230
※ 기관로그인 시 무료 이용이 가능합니다.
4,000원
원문정보
초록
- 영어
- Objectives: This was to evaluate the current usage of three erythropoietin stimulating agents (ESA) and their efficacy for management of anemia in peritoneal dialysis (PD) patients with chronic kidney disease. Methods: It was a retrospective comparative study through review of electronic medical records of chronic kidney disease patients undergoing PD at a tertiary teaching hospital from January 1998 to June 2013. Results: Average administration frequency was 1.66 times/week in EPO group, 0.75 times/week in DA group, and 0.19 times/week in MPG-EPO group. At the first 4 weeks, there were significant differences in mean hemoglobin levels between EPO and DA groups (9.25± 1.28 g/dL, 10.02±0.95 g/dL each, p = 0.018) and also in hemoglobin response rates (10.0%, 45.2% each, p = 0.008), but since after 4 week, there had been no significant differences. There also showed no significant differences in achievement of hemoglobin target between the two groups. When converted to MPG-EPO in EPO/DA groups, there showed a slight increase in hemoglobin levels of both groups. MPG-EPO was the highest compared with two other drugs by the average cost based on the average weekly dose. Conclusion: EPO, DA, and MPG-EPO showed similar effects in treatment of anemia of PD patients based on hemoglobin target range (11.0~12.0 g/dL) which NFK-K/DOQI guidelines suggest. Though the average cost of MPG-EPO was higher than the other two drugs, the number of PD patients using MPGEPO has increased and it is thought that long half-life and low administration frequency of MPG-EPO have improved the compliance of PD patients who have to self-administrate.
목차
Abstract
연구 방법
대상환자
자료수집 및 조사항목
분석기준
분석방법
연구 결과
대상 환자군의 특성
ESA 제제 사용현황
치료효과 비교
약품비용 비교
고찰
결론
참고문헌
키워드
anemia chronic kidney disease erythropoietin stimulating agent peritoneal dialysis저자
간행물 정보
발행기관
-
- 발행기관명
- 한국임상약학회 [Korean College of Clinical Pharmacy]
- 설립연도
- 1
- 분야
- 의약학>약학
- 소개
- 합리적 약물치료(rational pharmacotherapy)의 보장 및 증진을 궁극목적으로 하며 이를 달성하기 위해 임상약학의 발전과 회원 상호간의 친목을 도모한다.
간행물
-
- 간행물명
- 한국임상약학회지 [Korean Journal of Clinical Pharmacy]
- 간기
- 계간
- pISSN
- 1226-6051
- 수록기간
- 1991~2026
- 등재여부
- KCI 등재
- 십진분류
- KDC 518 DDC 615
이 권호 내 다른 논문 / 한국임상약학회지 제24권 제3호
피인용수 : 0건 (자료제공 : 네이버학술정보)
함께 이용한 논문 이 논문을 다운로드한 분들이 이용한 다른 논문입니다.
출처 : 네이버학술정보
0개의 논문이 장바구니에 담겼습니다.